Trihealth Cancer Institute

Cincinnati, Ohio 45242

3 studies enrolling now · 9 studies all time

What they study most

Colorectal Cancer, KEAP1 Gene Mutation, Locally Advanced or Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, NFE2L2 Gene Mutation, NRF2 Gene Mutation, NSCLC Harboring NRG1 Fusion, Non-Small Cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, Non-squamous Non-small-cell Lung Cancer, Relapsed and/or Refractory Multiple Myeloma (RRMM), Small Cell Lung Cancer

Studies at this site

• Tempus Small Cell Lung Cancer Observational Study (Sculptor) — Recruiting now
• GEMINI-NSCLC: NSCLC Biomarker Study — Recruiting now
• Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays — Recruiting now
• Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers — Stopped early
• A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma — Completed
• Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation — Completed
• A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) — Stopped early
• KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC — Stopped early
• A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components — Completed